The management department of gem company of Shenzhen stock exchange sent a letter of concern to Honz Pharmaceutical Co.Ltd(300086) on February 21, requesting to explain the specific basis and objectivity and authority of the company’s judgment that sulamin sodium for injection may be a potential drug for the treatment of covid-19 original strain and variant strain infection; Supplement the specific contents of the agreement signed between the company and Guangdong Institute of public health, including but not limited to the main contract terms such as the subject of the agreement, the term of the agreement, the amount of the agreement, the specific rights and obligations of relevant parties, the liability for breach of contract and the agreement on dispute resolution mechanism, and state whether the above matters meet the relevant information disclosure standards, Whether there is a situation of using voluntary information disclosure to cater to market hot spots and hype stock prices; Explain the current research and development stage, R & D investment, R & D investment required in the future and R & D steps to be carried out for each indication of sulamin sodium for injection, and whether the company’s funds are sufficient to support the R & D of each indication of sulamin sodium for injection in combination with the company’s long-term capital expenditure and short-term working capital arrangement.
© China Stock Market News